A Safety Study of SGN-CD19A for Leukemia and Lymphoma
Status:
Completed
Trial end date:
2017-05-30
Target enrollment:
Participant gender:
Summary
This is a phase 1, open-label, dose-escalation, multicenter study to evaluate the safety and
tolerability of SGN-CD19A in adult and pediatric patients with relapsed or refractory
B-lineage acute lymphoblastic leukemia (B-ALL), Burkitt lymphoma or leukemia, or B-lineage
lymphoblastic lymphoma (B-LBL).